Product pipeline includes EVOMELA® (melphalan) for injection, MARQIBO® (vinCRIStine sulfate LIPOSOME injection), ZEVALIN® (ibritumomab tiuxetan) for the greater China market, ENMD-2076 currently in Phase 2 trials, as well as entecavir and the other U.S. ANDA products.
CASI Pharmaceuticals (NASDAQ: CASI), is a U.S. biopharmaceutical company dedicated to rapidly bringing high quality pharmaceutical products and innovative oncology therapeutics to patients. Our integrated China/U.S. drug development strategy is cost-effective and can accelerate product registration.
Our business mission is to become an integrated pharmaceutical company with significant market presence in greater China, while establishing strategic partnerships for development and commercialization outside of China. Our patient-focused mission is to maximize patient access to high quality and innovative therapeutics in order to better patient lives and address significant unmet medical needs.
This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.
EVOMELA® (melphalan) for Injection, MARQIBO® (vinCRIStine sulfate LIPOSOME injection), ZEVALIN® (ibritumomab tiuxetan) and SPECTRUM PHARMACEUTICALS, INC. ® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. The SPECTRUM PHARMACEUTICALS logos are trademarks owned by Spectrum Pharmaceuticals, Inc.